ASH 2022 | The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, discusses findings from a clinical study which evaluated the efficacy and toxicity of reduced venetoclax exposure to the concurrent days of azacitidine administration in patients with difficult-to-treat acute myeloid leukemia (AML). Results indicated that limited venetoclax exposure with azacitidine induced similar response rates to conventional regimens, with an overall response rate (ORR) of 68%. Dr de Botton also comments on the main predictors for overall survival (OS) and event-free survival (EFS), including age and presence of TP53 mutation, and highlights how patients with favorable profiles, such as NPM1 and IDH1 mutations, had an even higher response rate. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.